Skip to main
BDSX

Biodesix (BDSX) Stock Forecast & Price Target

Biodesix (BDSX) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Biodesix is well-positioned for future growth, with a strong revenue stream from both its core lung disease testing and its expanding biopharma services segment. Its proprietary multi-omic AI platform and differentiated suite of liquid biopsy tests, combined with a large and underpenetrated addressable market, provide significant potential for long-term expansion. While there are risks including market competition and the need for continued revenue growth and potential additional capital, the company's experienced leadership and track record of product launches instill confidence in its ability to succeed.

Bears say

Biodesix is showing promising signs of improving financials with a narrowed net loss and improved cash burn, but the company's relatively thin cash position and continued reliance on equity issuance pose a significant risk. The company's revenue is also dependent on reimbursement decisions, and any changes to Medicare coverage could significantly impact earnings. Additionally, the company's future profitability hinges on reaching cash flow break-even, which may not be achieved before further dilution erodes potential upside.

Biodesix (BDSX) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biodesix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biodesix (BDSX) Forecast

Analysts have given Biodesix (BDSX) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Biodesix (BDSX) has a Strong Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biodesix (BDSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.